BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer

Breast Cancer Clinical Trial

— BRE-08  

Official title:

BRE-08: A Phase II Study of an All-Oral Adjuvant Chemotherapy Regimen of Cyclophosphamide, Methotrexate, and Capecitabine (CMC) for Early-Stage Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06085742
• Other study ID #: 2023-0429
• Status: Recruiting
• Phase: Phase 2
• Start date: November 22, 2023
• Est. completion date: September 2034

Study information

• Verified date: January 2024
• Source: University of Illinois at Chicago
• Contact: Abiola Ibreeheem, MD
• Phone: 312-413-1581
• Email: abiolai[@]uic.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy.

Description:

Participants who require adjuvant radiotherapy for locoregional management may opt to initiate radiotherapy following the fourth cycle of CMC with the final 4 cycles held during radiotherapy. Following completion of radiation therapy, participants may then resume with cycle 5 of CMC. The washout period before and after radiation therapy is a minimum of 2 weeks. Alternatively, patients may receive adjuvant radiotherapy after the completion of the final (8) cycle of CMC. The study team will collect data on cyclophosphamide, methotrexate, and capecitabine compliance at routine clinical visits every 3 weeks. In addition, standard electrolyte, chemistry and liver function laboratory monitoring will be conducted at each clinic visit

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: September 2034
• Est. primary completion date: September 2034
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years of age at time of consent
• ECOG performance status 0, 1, or 2
• Histologically confirmed invasive breast cancer documented by biopsy or surgical excision.
• Underwent potentially curative resection of primary breast tumor(s) with no gross residual local-regional disease (patients with microscopically positive margins are eligible if adjuvant radiotherapy is planned), with most recent breast or axillary surgery < 120 days prior to date of signed consent.
• No evidence of distant metastatic disease
• Treating Oncologist recommends adjuvant chemotherapy without concurrent biologic/targeted therapy. Patients may receive a CDK4/6 inhibitor after completion of all study treatment, concurrently with adjuvant endocrine therapy. Patients with a germline pathogenic/likely pathogenic variant in a DNA homologous repair gene (e.g. BRCA1, BRCA2, PALB2) may receive adjuvant PARP inhibitor therapy after completion of all study treatment.
• Tumor is estrogen receptor (ER)-positive (> 10% by IHC) and/or progesterone receptor (PR)-positive (> 10% by IHC), HER2-negative by IHC or FISH according to 2018 ASCO-CAP guidelines.
• High risk gene expression profile (either luminal B on MammaPrint/BluePrint, or Recurrence Score > 25 on Oncotype Dx). Study participants are not required to have a high risk gene expression profile if they have a clinical high-risk tumor, defined as:

Age < 50 and any of the following:

• Involvement of 1-3 axillary lymph nodes with metastatic carcinoma (N1mic/N1)
• grade 1 tumor > 3 cm; or grade 2 tumor > 2 cm; or grade 3 tumors > 1 cm (size based on pathological assessment of the maximal dimension of the invasive component of the tumor)
• pT1c-T2 and Ki-67 > 20%
• Presence of lymphovascular invasion

Age > 50 and the following:

• Primary tumor > 5 cm (pT3)
• AJCC pathologic stage:
• pT1-2/pN0-1 based on sentinel lymph node biopsy or axillary dissection
• stage IIIA (pT3N1 or pT1-3/N2) tumors are eligible . A high risk gene expression profile is not required for pathologic stage IIIA patients.
• Adequate organ function as defined in Table 1. All screening labs to be obtained within 30 days prior to registration.
• Patients with synchronous bilateral primary breast tumors or multiple ipsilateral primary breast tumors are eligible if the treating Oncologist determines that the CMC regimen is appropriate therapy for all primary tumors requiring chemotherapy.
• Able to provide written informed consent and HIPAA authorization for release of personal health information.
• Women of childbearing potential must agree to use 2 methods of birth control, at least one being a barrier form of contraception if they are sexually active with a male partner unless they are considered highly unlikely to conceive as defined in section 8.6, and cannot be pregnant or breast-feeding. A negative serum or urine pregnancy test is required per institutional practice guidelines.
• As determined at the discretion of the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study. Hematological Leukocytes =2,500/mm3 Platelet count = 100,000/mm3 Absolute Neutrophil Count (ANC) = 1,200/mm3 Hemoglobin (Hgb) = 9.0 g/dL Renal Creatinine/Calculated creatinine clearance (CrCl) Cr < 1.5 x upper limit of normal (ULN) or CrCl = 50 mL/min using the Cockcroft-Gault formula Hepatic Bilirubin Bilirubin = 1.5 × ULN. Subjects with Gilbert's syndrome may have a bilirubin > 1.5 × ULN, if no evidence of biliary obstruction exists Aspartate aminotransferase (AST) = 2.5 × ULN Alanine aminotransferase (ALT) = 2.5 × ULN

Exclusion Criteria:

• Prior cytotoxic chemotherapy for this breast cancer
• Any investigational agents administered during or within 2 weeks prior to start of CMC chemotherapy
• AJCC stage IIIB-IIIC or stage IV
• Active infection requiring systemic therapy
• Uncontrolled HIV/AIDS or active viral hepatitis
• Pregnant or nursing
• Require anticoagulation with warfarin. Anticoagulation with low molecular weight heparins, heparin, or direct oral anticoagulants (DOACs) is permitted.
• Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating medical oncologist.
• Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial.
• Other major comorbidity (e.g. advanced cardiopulmonary disease, uncontrolled diabetes mellitus) that may affect the safety or efficacy assessment of this investigational regimen, as determined by study PI
• Inability to swallow pills
• Any medical condition interfering with absorption of oral medications
• Any contraindication for any chemotherapy drug used in the CMC regimen
• Active and ongoing use of medicines known to alter metabolism or tolerability of component drugs in CMC.
• Prisoners
• Unable or unwilling to take a large number of oral pills

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Cyclophosphamide
60mg/m2 PO once a day (21 continuous days)
• Methotrexate
10mg/m2 PO BID on days 1, 8, and 15
• Capecitabine
825mg/m2 PO BID on days 1-14

Locations

Country	Name	City	State
United States	University of Illinois	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
University of Illinois at Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Relative Dose Intensity (RDI) in patients treated with the CMC regimen. RDI is defined as the sum total of delivered drug in mg/m2/week for each drug in the CMC regimen per the number of participants that have equal to or greater than 85%	Number of participants that have RDI of the CMC regimen is equal to or greater than 85%	1 year
Secondary	Safety of oral CMC regime per the number of participants experiencing adverse events	Number of participants having adverse event using the NCI Common Terminology Criteria for Adverse Events (CTCAE), version 5	1 year
Secondary	Invasive Disease Free Survival (iDFS)	Number of participants that have iDFS, defined as the time from enrollment to; documentation of the first of the following: invasive cancer in the ipsilateral breast/chest wall or regional nodes, contralateral invasive breast or regional nodes, distant metastases, or death from any cause	10 years
Secondary	Distant Disease Free Survival (DDFS)	Number of participants that have DDFS defined as the time from enrollment to documentation of distant metastases or death from any cause.	10 years
Secondary	Overall Survival (OS)	Number of participants that have OS defined as the time from study enrollment to the date of the subject's death	10 years
Secondary	Participant outcomes using the Quality of Life (QOL) and EORTC QOL-C30 questionnaires	Number of participants having good outcome versus low outcomes. High score means worse health outcomes and low score means better health outcomes	10 years
Secondary	Protocol therapy interruption	Number of participants that have protocol therapy interruption	10 years
Secondary	Discontinuation of protocol therapy	Number of participants that have discontinuation of protocol therapy	10 years
Secondary	Rates of dose reduction of cyclophosphamide	Number of participants that have dose reduction of cyclophosphamide	10 years
Secondary	Rates of dose reduction of methotrexate	Number of participants that have dose reduction of methotrexate	10 years
Secondary	Rates of dose reduction of capecitabine	Number of participants that have dose reduction of capecitabine	10 years